Updated:
Mereo BioPharma Group plc
Mereo BioPharma Group plc is a London-based biopharmaceutical company developing rare disease therapeutics. Publicly traded on NASDAQ.
Mereo BioPharma Group plc
Mereo BioPharma Group plc was established to acquire and advance clinical-stage drug candidates from larger pharmaceutical companies. The company's strategy centers on identifying promising assets that have been deprioritized by their originators and shepherding them through to regulatory approval. The company's pipeline includes setrusumab for osteogenesis imperfecta, alvelestat for alpha-1 antitrypsin deficiency-associated lung disease, and acero-cortistat for Duchenne muscular dystrophy. These programs address rare disease indications with high unmet medical need. Mereo's business model involves licensing or acquiring these assets and conducting further clinical development. Mereo BioPharma Group plc is headquartered in London, with an additional office in Redwood City, California. The company is listed on NASDAQ under the ticker MREO and on Euronext Brussels. As a publicly traded entity, it reports financial results quarterly per SEC requirements. The company's structural differentiator is its asset-centric model: rather than building a diversified pipeline from scratch, it cherry-picks late-stage clinical assets from big pharma, reducing early-stage risk while targeting diseases where existing treatments are limited or absent.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Sector focus
Frequently asked questions
What is Mereo BioPharma's clinical pipeline?
Mereo BioPharma's pipeline includes setrusumab (for osteogenesis imperfecta), alvelestat (for alpha-1 antitrypsin deficiency-associated lung disease), and acero-cortistat (for Duchenne muscular dystrophy). These are all late-stage clinical assets acquired from larger pharmaceutical companies. The company focuses on rare disease indications where treatment options are limited.
How does Mereo BioPharma source its drug candidates?
Mereo's strategy is to identify and in-license clinical-stage drug candidates that have been deprioritized by larger pharmaceutical companies. The company then funds and manages the clinical development required to achieve regulatory approval. This asset-centric model reduces early-stage research risk.
Where is Mereo BioPharma headquartered?
Mereo BioPharma Group plc is headquartered in London, United Kingdom, with an additional office in Redwood City, California. The company is listed on both NASDAQ and Euronext Brussels, reflecting a dual-market presence.
Is Mereo BioPharma profitable?
As a publicly traded biopharmaceutical company in the clinical stage, Mereo BioPharma typically reports net losses reflecting research and development expenditures. The company does not yet have approved products generating revenue. Investors should review the firm's SEC filings for detailed financial information.
What rare diseases does Mereo BioPharma target?
Mereo's pipeline targets alpha-1 antitrypsin deficiency (a genetic condition causing lung and liver disease), osteogenesis imperfecta (a genetic bone fragility disorder sometimes called brittle bone disease), and Duchenne muscular dystrophy (a progressive muscle-wasting condition). These are all serious rare diseases with significant unmet medical need.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: